10/531,145

```
=> d his

     (FILE 'HOME' ENTERED AT 15:39:32 ON 10 JAN 2008)

     FILE 'MEDLINE, CAPLUS, BIOSIS, SCISEARCH, LIFESCI' ENTERED AT 15:39:54 ON
     10 JAN 2008
L1          3425 S AUTOLOGOUS(4A)T(4A)LYMPHOCYTE
L2        124385 S PBMC OR PERIPHERAL(W)BLOOD(W)MONONUCLEAR(3A)CELL
L3           305 S L1 AND L2
L4          4070 S (RETROVIRUS OR RETROVIRAL OR LENTIVIR? OR HIV OR MMLV)(10A)(I
L5             2 S L3 AND L4
L6             2 DUP REM L5 (0 DUPLICATES REMOVED)
L7        729938 S RETROVIRUS OR RETROVIRAL OR LENTIVIR? OR HIV OR MMLV
L8        243741 S INTERLEUKIN-2 OR IL-2
L9            45 S L3 AND L7
L10           12 S L8 AND L9
L11            5 DUP REM L10 (7 DUPLICATES REMOVED)

=> d au ti so pi 1-2 l6

L6   ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2008 ACS on STN
IN   Liu, Ke; Rosenberg, Steven A.
TI   Preparation of lymphocytes that express interleukin-2 and uses thereof in
     the treatment of cancer
SO   PCT Int. Appl., 26 pp.
     CODEN: PIXXD2
     PATENT NO.          KIND   DATE        APPLICATION NO.          DATE
     ---------------     ----   --------    -------------------      --------
PI   WO 2004034789        A1     20040429    WO 2002-US33243          20021015
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
             PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
             UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
             FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF,
             CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     CA 2501087          A1     20040429    CA 2002-2501087          20021015
     AU 2002353822       A1     20040504    AU 2002-353822           20021015
     EP 1558085          A1     20050803    EP 2002-789213           20021015
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY; AL, TR, BG, CZ, EE, SK
     US 2005233451       A1     20051020    US 2005-531145           20050519

L6   ANSWER 2 OF 2  CAPLUS  COPYRIGHT 2008 ACS on STN
AU   Ennen, Joachim; Seipp, Inka; Norley, Stephen G.; Kurth, Reinhard
TI   Decreased accessory cell function of macrophages after infection with
     human immunodeficiency virus type 1 in vitro
SO   European Journal of Immunology (1990), 20(11), 2451-6
     CODEN: EJIMAF; ISSN: 0014-2980


=> d au ti so pi 1-5 l11

L11  ANSWER 1 OF 5    MEDLINE on STN                    DUPLICATE 1
AU   Liu Shujuan; Riley John; Rosenberg Steven; Parkhurst Maria
TI   Comparison of common gamma-chain cytokines, interleukin-
     2, interleukin-7, and interleukin-15 for the in vitro generation
     of human tumor-reactive T lymphocytes for adoptive cell transfer therapy.
SO   Journal of immunotherapy (Hagerstown, Md. : 1997), (2006 May-Jun) Vol. 29,
     No. 3, pp. 284-93.
     Journal code: 9706083. ISSN: 1524-9557.
```

L11 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN
IN Liu, Ke; Rosenberg, Steven A.
TI Preparation of lymphocytes that express interleukin-2 and uses thereof in the treatment of cancer
SO PCT Int. Appl., 26 pp.
CODEN: PIXXD2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004034789	A1	20040429	WO 2002-US33243	20021015
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2501087	A1	20040429	CA 2002-2501087	20021015
AU 2002353822	A1	20040504	AU 2002-353822	20021015
EP 1558085	A1	20050803	EP 2002-789213	20021015
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
US 2005233451	A1	20051020	US 2005-531145	20050519

L11 ANSWER 3 OF 5 MEDLINE on STN DUPLICATE 2
AU Ho M; Armstrong J; McMahon D; Pazin G; Huang X L; Rinaldo C; Whiteside T; Tripoli C; Levine G; Moody D; +
TI A phase 1 study of adoptive transfer of autologous CD8+ T lymphocytes in patients with acquired immunodeficiency syndrome (AIDS)-related complex or AIDS.
SO Blood, (1993 Apr 15) Vol. 81, No. 8, pp. 2093-101.
Journal code: 7603509. ISSN: 0006-4971.

L11 ANSWER 4 OF 5 MEDLINE on STN DUPLICATE 3
AU Ennen J; Seipp I; Norley S G; Kurth R
TI Decreased accessory cell function of macrophages after infection with human immunodeficiency virus type 1 in vitro.
SO European journal of immunology, (1990 Nov) Vol. 20, No. 11, pp. 2451-6.
Journal code: 1273201. ISSN: 0014-2980.

L11 ANSWER 5 OF 5 MEDLINE on STN
AU Clerici M; Stocks N I; Zajac R A; Boswell R N; Shearer G M
TI Accessory cell function in asymptomatic human immunodeficiency virus-infected patients.
SO Clinical immunology and immunopathology, (1990 Feb) Vol. 54, No. 2, pp. 168-73.
Journal code: 0356637. ISSN: 0090-1229.

=> d ab 3-5 l11

L11 ANSWER 3 OF 5 MEDLINE on STN DUPLICATE 2
AB Based on preclinical studies showing that CD8+ T lymphocytes of human immunodeficiency syndrome (HIV)-infected subjects have anti-HIV activities, a phase 1 study was undertaken to determine the safety and feasibility of infusing in vitro purified, activated, and expanded CD8+ cells as a therapeutic measure in seven patients with acquired immunodeficiency syndrome (AIDS)-related complex (ARC) or AIDS. Autologous CD8+ cells were first selectively isolated in monoclonal antibody-coated flasks from peripheral blood mononuclear cells recovered by leukapheresis. They were

then cultured and expanded with phytohemagglutinin and recombinant interleukin-2 (rIL-2) before infusion. Five cycles of isolations and infusions of increasing numbers of CD8+ T cells were achieved in five of seven subjects. Five cycles could not be completed in two subjects with AIDS whose CD4+ cell counts were < or = 48/microliters. Infusions of CD8+ cells alone were well tolerated. Four patients received rIL-2 by continuous infusion for 5 days with their final cycle of CD8+ cells. All developed reversible adverse effects attributable to rIL-2. After infusion, 111In-labeled CD8+ cells quickly accumulated in the lungs, with less than 10% of the labeled cells remaining in the circulation. After 24 hours, labeled CD8+ cells were reduced in the lungs, but increased and persisted in liver, spleen, and bone marrow. Four of five patients who were treated with multiple infusions of CD8+ cells have improved or remained clinically stable, and the fifth developed Pneumocystis carinii pneumonia but recovered. This study demonstrated that infusion of autologous, in vitro expanded and activated CD8+ cells was feasible and clinically well tolerated in five of seven subjects with advanced HIV infections.

L11 ANSWER 4 OF 5 MEDLINE on STN DUPLICATE 3

AB Peripheral blood monocytes from human immunodeficiency virus (HIV)-infected individuals or AIDS-related complex/AIDS patients ex vivo exhibit distinct alterations in some but not all immune functions. In studies presented here, monocytes from healthy donors were infected with HIV 1 in vitro and co-cultures with autologous uninfected T lymphocytes were set up. The monocyte/macrophage (M phi)-dependent T cell function was determined by measurement of proliferative and secretory [interleukin (IL) 2, interferon-gamma] responses to lectin (phytohemagglutinin), mitogen (anti-CD3 monoclonal antibody), or recall antigen (tetanus toxoid, tuberculin). Accessory function of M phi was normal after HIV infection when optimal amounts (10%-20%) were added to the T lymphocytes. However, HIV infection of M phi significantly decreased T cell proliferative responses and secretion of IL2 when supplemented at limited dilution (0.5%-5%), although interferon-gamma production was not affected. Whereas the lipopolysaccharide-triggered M phi production of IL1 was not impaired by HIV 1 infection, there was a significant decrease in this response when anti-CD3 monoclonal antibody or tetanus toxoid were used to trigger the peripheral blood mononuclear cells. The impairment of proliferation of T lymphocytes in the presence of HIV 1-infected M phi could be overcome by addition of exogenous IL 1. Taken together, these data clearly show that the mononuclear phagocyte-dependent enhancement of stimulated T cell proliferation and lymphokine secretion is decreased when the restricted numbers of monocytes/M phi are HIV 1 infected. There are, therefore, two possible roles of M phi in HIV infection and progression to disease. First, as a reservoir and vehicle for dissemination of the virus, and second, as an immune cell whose essential functions are impaired by infection.

L11 ANSWER 5 OF 5 MEDLINE on STN

AB Peripheral blood mononuclear cells from human immunodeficiency virus seropositive (HIV+) individuals who did not exhibit symptoms of acquired immunodeficiency syndrome (AIDS) (Walter Reed Stage 1 patients) were tested for accessory cell function for presentation of recall antigens to autologous T lymphocytes and for presentation of HLA alloantigens to T lymphocytes from healthy, HIV- donors. Neither experimental model indicated a defect in accessory cell function at this early stage after HIV infection, although our study does not exclude the possibility of accessory cell dysfunction at a later stage of AIDS development.

Refine Search

Search Results -

Terms	Documents
L5 and L8	17

Database:
US Pre-Grant Publication Full-Text Database
US Patents Full-Text Database
US OCR Full-Text Database
EPO Abstracts Database
JPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Search: L9

Refine Search | Recall Text | Clear | Interrupt

Search History

DATE: Thursday, January 10, 2008 Purge Queries | Printable Copy | Create Case

Set Name side by side	Query	Hit Count	Set Name result set
	DB=PGPB,USPT; PLUR=YES; OP=AND		
L9	l5 and L8	17	L9
L8	l3 near10 l4	976	L8
L7	l4 and L6	206	L7
L6	l3 and L5	236	L6
L5	l1 and l2	310	L5
L4	interleukin-2 or il-2	35055	L4
L3	retrovirus or retroviral or lentivir$ or hiv or mmlv	92809	L3
L2	pbmc or peripheral adj blood adj mononuclear near3 cell	16589	L2
L1	autologous near4 t near4 lymphocyte	553	L1

END OF SEARCH HISTORY

Generate Collection | Print

Search Results - Record(s) 1 through 17 of 17 returned.

☐ 1. 20070081942. 20 Nov 06. 12 Apr 07. Gene differentially expressed in breast and bladder cancer, and encoded polypeptides. Zauderer; Maurice, et al. 424/1.49; 424/178.1 435/320.1 435/328 435/69.1 530/388.22 530/391.1 536/23.53 A61K39/395 20060101 A61K51/00 20060101 C07H21/04 20060101 C07K16/46 20060101 C12P21/06 20060101

☐ 2. 20050249711. 07 Feb 05. 10 Nov 05. Allogeneic vaccine and methods to synthesize same. Gansbacher, Bernd. 424/93.21; 424/85.2 435/372 A61K048/00 C12N005/08 A61K038/20.

☐ 3. 20050233451. 19 May 05. 20 Oct 05. Methods of preparing lymphocytes that express interleukin-2 and their use in the treatment of cancer. Liu, Ke, et al. 435/372; C12N005/08.

☐ 4. 20050169900. 31 Mar 05. 04 Aug 05. Allogeneic vaccine and methods to synthesize same. Gansbacher, Bernd. 424/93.21; 424/85.2 424/85.6 435/369 435/456 A61K048/00 A61K038/21 C12N005/08 C12N015/867.

☐ 5. 20040063907. 10 Jun 03. 01 Apr 04. Gene differentially expressed in breast and bladder cancer and encoded polypeptides. Zauderer, Maurice, et al. 530/350; 435/320.1 435/325 435/69.1 536/23.5 C07K014/705 C07H021/04 C12P021/02 C12N005/06.

☐ 6. 20030166277. 12 Apr 01. 04 Sep 03. Targeted vaccine delivery systems. Zauderer, Maurice, et al. 435/372; 424/178.1 530/391.1 A61K039/395 C12P021/08 C07K016/46.

☐ 7. 20020155447. 04 Apr 01. 24 Oct 02. Gene differentially expressed in breast cancer, and encoded polypeptides. Zauderer, Maurice, et al. 435/6; 435/226 435/320.1 435/325 435/69.1 435/7.23 536/23.2 C12Q001/68 G01N033/574 C07H021/04 C12N009/64 C12P021/02 C12N005/06.

☐ 8. 20010038841. 05 Jun 01. 08 Nov 01. Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine. Hiserodt, John C., et al. 424/130.1; 424/277.1 435/368 A61K039/395 A61K039/00 C12N005/08.

☐ 9. 20010036458. 05 Jun 01. 01 Nov 01. Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokline. Hiserodt, John C., et al. 424/130.1; 424/277.1 435/368 A61K039/395 A61K039/00 C12N005/08.

☐ 10. 7268207. 04 Apr 01; 11 Sep 07. Gene differentially expressed in breast and bladder cancer, and encoded polypeptides. Zauderer; Maurice, et al. 530/300; 424/184.1 424/185.1 530/350. A61K38/00 20060101 C07H21/00 20060101 C07H21/02 20060101 C07H5/00 20060101 C07K14/00 20060101 C07K16/00 20060101 C07K17/00 20060101 C07K2/00 20060101 C07K4/00 20060101 C07K5/00 20060101 C08B37/00 20060101 C08B37/08 20060101 .

☐ 11. 7264820. 05 Jun 01; 04 Sep 07. Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokline. Hiserodt; John C., et al. 424/277.1;. A61K39/00 20060101 .

☐ 12. 6316257. 03 Mar 97; 13 Nov 01. Modified rapid expansion methods ("modified-REM") for in vitro propagation of T lymphocytes. Flyer; David C., et al. 435/372.3; 435/325 435/343.2 435/372

435/373 435/375 435/383 435/384 435/386 530/351 530/388.7. C12N005/08 C12N005/16 C12N005/00 C07K016/00 .

☐ 13. 6277368. 24 Jul 97; 21 Aug 01. Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine. Hiserodt; John C., et al. 424/93.21; 424/277.1 424/85.1 424/85.2 424/85.6 424/93.1 424/93.3 424/93.7 424/93.71 435/325. A01N063/00 C12N015/85 A61K035/12 A61K035/19 .

☐ 14. 6121044. 12 Jul 95; 19 Sep 00. Potent antigen presenting cell composition. Peshwa; Madhusudan Viswanath, et al. 435/325; 435/2 435/372 435/373 435/375 435/382 435/395. C12N005/00 C12N005/02 C12N005/06 .

☐ 15. 6074836. 04 Apr 96; 13 Jun 00. Method of marking eukaryotic cells. Bordignon; Claudio, et al. 435/7.24; 424/93.21 435/366 435/372.3 435/7.21. C12N005/00 G01N033/53 A01N063/00 .

☐ 16. 6040177. 13 Mar 96; 21 Mar 00. High efficiency transduction of T lymphocytes using rapid expansion methods ("REM"). Riddell; Stanley R., et al. 435/372.3; 435/2 435/320.1 435/373 435/374 435/375 435/377 435/383 435/384 435/455 530/351 530/388.75 536/23.1 536/23.72. C12N005/10 C12N015/11 C07K014/55 C07K016/28 .

☐ 17. 5827642. 03 Oct 94; 27 Oct 98. Rapid expansion method ("REM") for in vitro propagation of T lymphocytes. Riddell; Stanley R., et al. 435/2; 424/93.71 435/372.3 435/373 435/375 435/383 435/384 435/386. C12N005/02 C12N005/08 A01N001/02 A61K035/12 .

Generate Collection | Print

Terms	Documents
L5 and L8	17

Prev Page Next Page Go to Doc#